Special Issue

Targeted Drug Delivery in Autoimmune Diseases

Message from the Guest Editors

Autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus, are chronic conditions affecting people worldwide. Several potent drugs are available for the treatment of these diseases; however, their prolonged use is associated with severe adverse reactions. This is partly because while these drugs are intended to target the diseased site (e.g., the joints or the brain), they are still distributed systemically after oral intake or injection. Furthermore, many of these drugs have limitations of reduced efficacy as well as poor solubility and bioavailability. Therefore, better drug delivery modalities are needed to overcome these significant limitations. Advancements in nanotechnology and the identification of tissue-homing/cell-specific ligands are paving the way for targeted drug delivery for various tumors. Thus, there is now an impetus to develop and apply similar approaches for the treatment of autoimmune diseases. Authors are cordially invited to submit their original research papers, reviews and communications, addressing the aforementioned areas.

Guest Editors

Prof. Dr. Kamal Moudgil

Department of Microbiology and Immunology, University of Maryland School of Medicine, 685 W. Baltimore Street, HSF-1, Suite 380, Baltimore, MD 21201, USA

Prof. Dr. Tambet Teesalu

Laboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14b, 50411 Tartu, Estonia

Deadline for manuscript submissions

closed (20 March 2024)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/187302

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

